What guidance did Axogen's management provide for the next earnings period?

Did Axogen beat or miss consensus estimates last quarter?

What factors drove the changes in Axogen's revenue and profit?

What were the key takeaways from Axogen’s earnings call?

What were the key takeaways from Axogen's earnings call?

What is Axogen's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Axogen year over year?

What is Axogen's gross profit margin?

- **Revenue Surge**: Q3 2025 revenue up 23.5% YoY to $60.1 million, driven by Avance Nerve Graft adoption across all target markets.
- **BLA Milestone**: FDA extended BLA approval to December 5, 2025, with 12 years of exclusivity post-approval.
- **Coverage Expansion**: 64% of commercial payers now cover nerve repair, up from 55% last quarter.
- **Financial Strength**: Adjusted EBITDA $9.2 million (15.4% margin), cash balance $39.8 million.
- **Strategic Momentum**: Met hiring goals for breast and OMF, trained 62 breast surgeon pairs (75 target), and secured 10 new clinical publications.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached $60.1 million, up 23.5% YoY, driven by Avance Nerve Graft adoption across extremities, oral maxillofacial (OMF), head and neck, and breast markets.
- **Case Stock Program Impact**: Discontinuation of the case stock sales program added $1.6 million to Q3 revenue as customers transitioned to direct sales. High potential accounts contributed 64% of growth, though case stock effects reduced this by 4%.
- **Strategic Initiatives**: Met hiring goals for breast (22 specialists) and OMF (4 market managers). Surgeon training on track: 62 breast surgeon pairs trained (75 target), 97 extremities surgeons trained (105 target).
- **Clinical & Regulatory Progress**: 10 new peer-reviewed publications, bringing total to 339. FDA extended BLA approval to December 5, 2025, with 12 years of exclusivity post-approval. Coverage expanded to 64% of commercial payers.

**【CFO Financial Commentary】**
- **Financial Performance**: Gross profit $46 million (76.6% margin), up from 74.9% YoY. Adjusted EBITDA $9.2 million (15.4% margin). Cash balance $39.8 million, up $3.9 million QoQ.
- **Guidance Update**: Raised 2025 revenue guidance to at least 19% growth ($222.8 million+). Gross margin expected 73-75%, with BLA-related costs impacting margin by ~1%.

**【Q&A Highlights】**
- **BLA Timeline**: FDA interactions positive; BLA approval expected by December 5, 2025. No immediate impact from government shutdown.
- **Coverage Expansion**: 1.1 million new covered lives in Q3, total 18.1 million year-to-date. Engaging 3 national payers to remove investigational labels.
- **Prostate Market**: Completed 100 clinical cases by year-end; outcomes to inform 2026 strategy. Level 1 studies planned for breast and other markets.
- **International Strategy**: Post-BLA, evaluate opportunities in Europe and Asia-Pacific.


Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 18.3% YoY to $56.7 million, driven by Avance Nerve Graft adoption and high-potential account productivity.
- **BLA Milestone**: FDA approval expected in September 2025, securing 12 years of exclusivity.
- **Coverage Expansion**: 55% commercial payer coverage achieved, with 17 million lives added year-to-date.
- **Financial Health**: Adjusted EBITDA $9.3 million, up 66% YoY; 2025 revenue guidance raised to ≥$219 million.

**【CEO Summary Section】**
- Q2 2025 revenue reached $56.7 million, up 18.3% YoY, driven by 15% unit volume growth and 3% price increase across extremities, oral maxillofacial, and breast markets.
- Avance Nerve Graft adoption accelerated, with 70% of revenue growth from high-potential accounts (780 total) and 21% YoY productivity increase in these accounts.
- BLA approval for Avance Nerve Graft expected in September 2025, securing 12 years of market exclusivity.
- Breast resensation procedures grew 17% YoY, with 280 surgeons performing procedures in Q2.
- Surgeon training expanded: 75 breast, 105 extremities, and 45 oral/maxillofacial surgeons trained by year-end 2025.
- Coverage expansion added 10 million lives in Q2, bringing commercial payer coverage to 55%.

**【CFO Financial Commentary】**
- Gross profit $42 million (74.2% margin), up from $35.3 million (73.8% margin) in Q2 2024, due to lower inventory write-offs and cost optimization.
- Operating expenses $40.3 million, 3.5% of revenue, reflecting improved efficiency.
- Adjusted EBITDA $9.3 million, up from $5.6 million YoY.
- Full-year 2025 guidance: Revenue ≥$219 million (17% growth), gross margin 73-75%, net cash flow positive.
- BLA-related costs expected to impact Q3 gross margin by ~1%, with 2/3 as non-cash stock compensation.

**【Q&A Highlights】**
- **BLA Progress**: FDA late-cycle meeting completed without issues; approval process on track for September 2025.
- **Sales Productivity**: 641 active high-potential accounts, with 124 sales reps and 19 breast specialists by end of Q2.
- **Coverage Momentum**: 17 million lives added year-to-date, targeting near-complete commercial coverage by 2030.
- **Gross Margin Trends**: Sequential improvement due to cost controls, with long-term upside from scale in Axogen processing center.
- **Breast Market Growth**: 17% YoY procedure growth, driven by surgeon training and expanded sales force (targeting 22 reps by end-2025).

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: Q1 2025 revenue up 17.4% to $48.6M, driven by 14% unit growth and 3% price increase
- **BLA Milestone**: Avance Nerve Graft BLA approval expected September 2025 with 12 years exclusivity
- **Gross Margin Challenge**: Q1 gross margin 71.9% (down 690bps YoY) due to new facility costs and write-offs
- **Breast Market Expansion**: 254 active surgeons (+16% YoY), 22 sales specialists planned by Q3
- **Head/Neck Growth**: 5 new market development managers added to accelerate adoption in mandible reconstruction

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue reached $48.6 million, up 17.4% YoY, driven by 14% unit volume growth and 3% price increase. Breast market revenue grew 16% YoY, with 254 active surgeons performing procedures.
- **High-Potential Accounts**: 566 active high-potential accounts (Level I trauma centers hospitals) generated 66% of growth, with average account productivity up 24% YoY. 780 total high-potential accounts identified.
- **Market Expansion**: Added 5 sales reps in extremities and 5 market development managers in head/neck. Breast sales team expanded from 12 to 22 specialists, on track for Q3 completion.
- **BLA Approval Progress**: Avance Nerve Graft BLA on track for September approval, with 12 years of exclusivity. Q3 will incur $2M one-time costs (67% non-cash).
- **Clinical Pipeline**: 8 new peer-reviewed publications validate nerve repair algorithm. Extremities Level 1 study vs autograft expected to complete protocol design by year-end.

**【CFO Financial Commentary】**
- **Gross Margin**: 71.9% (down 690bps YoY) due to higher Avance production costs at new Dayton facility and $1.5M inventory write-offs. Expects improvement post-BLA approval.
- **Operating Expenses**: Total OpEx $36.6M (-1.4% YoY). Sales efficiency improved (43.3% of rev vs 47.9% YoY). R&D down 17.8% to $6.1M.
- **Cash Flow**: Ended Q1 with $28.1M cash (vs $39.5M Q4). Guided for cash flow positive full year.
- **Guidance**: Full-year 2025 revenue growth 15-17%, gross margin 73-75% (including 1ppt BLA impact).

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 17.8% YoY in 2024, driven by nerve repair algorithm adoption across extremities, breast, and OMF markets.
- **Strategic Ambition**: 15%-20% CAGR target for 2025-2029, with $5 billion U.S. TAM expansion into prostatectomy and international markets.
- **Breast Business Acceleration**: Salesforce doubling to 24 reps, targeting 30%+ CAGR in neurotization procedures.
- **BLA Milestone**: FDA approval expected in September 2025, with 12 years of market exclusivity.
- **Profitability Focus**: 2025 guidance includes 15%-17% revenue growth, 73%-75% gross margin, and net cash flow positivity.

**【CEO Summary Section】**
- Full year 2024 revenue: $187.3 million (17.8% YoY growth), driven by adoption of the nerve repair algorithm across extremities, breast, and OMF markets.
- Q4 2024 revenue: $49.4 million (15.1% YoY growth), with 11% unit volume growth and 4% price increase.
- BLA submission for Avance Nerve Graft completed in Q3 2024; FDA approval expected in September 2025, with 12 years of market exclusivity.
- Strategic priorities for 2025-2029: 15%-20% CAGR, focusing on high potential accounts (Level 1 trauma centers, academic hospitals), breast neurotization expansion, and prostatectomy market development.

**【CMO Strategic Plan Highlights】**
- Total Addressable Market (TAM): $5 billion in the U.S., including extremities (>$1 billion), breast (fastest-growing), and OMF/head & neck.
- Growth strategies:
  - **Extremities**: Advocate for Avance as standard of care, optimize patient journey, expand into lower extremities.
  - **Breast**: Double salesforce to 24 reps, invest in surgeon education, and generate Level 1 clinical evidence.
  - **Prostatectomy**: Develop surgical protocols, complete clinical studies, and prepare for commercial launch.
- Operational efficiency: Invest in manufacturing to improve gross margin, target 73%-75% in 2025.

**【CFO Financial Review & Guidance】**
- Q4 2024 financials:
  - Gross margin: 76.1% (up from 74.6% YoY)
  - Sales & marketing expenses: 40.6% of revenue (down from 46.9% YoY)
  - R&D expenses: $6.7 million (down 6.2% YoY)
  - Adjusted EBITDA: $6.7 million (vs. $0.6 million YoY)
- 2025 guidance:
  - Revenue: 15%-17% growth
  - Gross margin: 73%-75% (including $2 million one-time BLA costs)
  - Cash flow: Net positive for the year, with Q1 cash outflow due to bonuses and sales meetings.

**【Q&A Key Takeaways】**
- **TAM Expansion**: New $5 billion TAM includes prostatectomy and international markets; core markets re-evaluated with better addressability metrics.
- **Profitability Balance**: 2025 focus on 15%-17% revenue growth while maintaining cash flow positivity; 2025 gross margin guidance reflects BLA-related costs.
- **Salesforce Expansion**: Breast salesforce doubling to 24 reps; OMF and prostatectomy teams growing for market development.
- **BLA Progress**: FDA engagement active; no delays expected; 2/3 of $2 million costs are non-cash stock comp.
- **Breast Market Momentum**: Resensation technique adoption accelerating; 2025 investments in education and infrastructure to support 30%+ CAGR.


AXGN

AXGN fundamentals

Earnings Call

You can ask Aime